Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-VISTA x MSLN bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Y Biologics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The **anti-VISTA x MSLN bispecific antibody** is an experimental immunotherapy developed by **Y-Biologics** for the treatment of **epithelioid malignant pleural mesothelioma (MPM)**. This bispecific antibody (BsAb) simultaneously targets **Mesothelin (MSLN)**, a tumor-associated antigen highly expressed in epithelioid MPM, and **V-domain Ig suppressor of T cell activation (VISTA)**, an immune checkpoint protein that contributes to the immunosuppressive tumor microenvironment. By dual-targeting, the antibody aims to localize to the tumor site via MSLN binding while blocking VISTA-mediated immune evasion. Preclinical studies indicate that the BsAb exhibits improved binding affinity and antibody-dependent cell cytotoxicity (ADCC) activity compared to monotherapy. It also serves as the structural foundation for a trispecific immunocytokine, created by fusing the BsAb with an interferon-beta (IFN-β) mutein to further enhance anti-tumor immune responses through both direct cytotoxicity and indirect activation of immune cells.
- Other names
- VISTA x MSLN bispecific antibody
02
Targets
MesothelinVISTA
Beyond the preview
Go deeper on anti-VISTA x MSLN bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-VISTA x MSLN bispecific antibody.